<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704024</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300006586</org_study_id>
    <nct_id>NCT04704024</nct_id>
  </id_info>
  <brief_title>Reducing Vertical Transmission of Hepatitis B in Africa</brief_title>
  <acronym>REVERT-B</acronym>
  <official_title>A Phase III, Randomized, 2x2 Factorial Trial to Assess the Efficacy of Antiviral Therapy in Women and Infants in Reducing Vertical Transmission of Hepatitis B in Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus is an infection that can be easily transmitted from women to newborns at&#xD;
      the time of delivery. Our objective is to identify novel options that are effective and safe&#xD;
      in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing&#xD;
      Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new&#xD;
      strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the&#xD;
      risk of hepatitis B transmission. The study will measure efficacy, safety, tolerability and&#xD;
      adherence to medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The REVERT-B trial is a multi-center, phase III, randomized 2x2 factorial study designed to&#xD;
      test the efficacy of early maternal TDF vs standard duration and neonatal 3TC prophylaxis&#xD;
      compared to matching placebo in preventing HBV MTCT. Eligible pregnant women with HBV in&#xD;
      prenatal care (n=450) will be randomized 1:1:1:1 to one of four maternal and neonatal&#xD;
      prophylaxis combinations (shown as A-D in the figure below). Women will initiate daily oral&#xD;
      TDF early (2nd trimester) or at the standard time per WHO guidelines (3rd trimester) and will&#xD;
      continue TDF until delivery. The current WHO standard of care in pregnant women with HBV&#xD;
      (EAg+) in Cameroon is TDF prophylaxis from 28 weeks until delivery. Newborns will receive&#xD;
      liquid 3TC or matching placebo for the first six months of life to provide coverage until the&#xD;
      vaccine series is complete. All infants in the study will be offered the 4-dose HBV vaccine&#xD;
      series starting at birth.&#xD;
&#xD;
      The 2x2 factorial design allows for two simultaneous studies where we first assess efficacy&#xD;
      of early maternal prophylaxis (Aim 1) and secondarily assess efficacy of neonatal prophylaxis&#xD;
      (Aim 2). The study endpoint for both aims is the MTCT rate (proportion of infants HBsAg+) at&#xD;
      6-9 months of age. Women and infants will be followed until 6-9 months after delivery and&#xD;
      subaims will assess safety and adherence to maternal TDF and neonatal 3TC. Plasma testing&#xD;
      will be used to measure medication adherence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2x2 factorial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pregnant women will be randomized in open label fashion to early or late initiation of TDF.&#xD;
Infants will be randomized to receive lamivudine or matching placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vertical Transmission of hepatitis B Infection</measure>
    <time_frame>6-9 months of age</time_frame>
    <description>The proportion of infants with Hepatitis B surface antigen positivity (SAg+)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virologic Suppression</measure>
    <time_frame>at delivery</time_frame>
    <description>The proportion of women with a suppressed HBV DNA viral load (&lt;10 IU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In utero HBV infection</measure>
    <time_frame>at birth</time_frame>
    <description>HBV infection (SAg+, PCR positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Adherence to TDF</measure>
    <time_frame>8 weeks after starting medication</time_frame>
    <description>HPLC measurement of serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Adherence to TDF</measure>
    <time_frame>at delivery</time_frame>
    <description>HPLC measurement of serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Adherence to 3TC</measure>
    <time_frame>12 weeks after starting 3TC</time_frame>
    <description>HPLC measurement of serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Adherence to 3TC</measure>
    <time_frame>24 weeks after starting 3TC</time_frame>
    <description>HPLC measurement of serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Flare</measure>
    <time_frame>12 weeks after delivery</time_frame>
    <description>Increase in ALT (&gt;2x ULN) after stopping TDF at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Flare</measure>
    <time_frame>24 weeks after delivery</time_frame>
    <description>Increase in ALT (&gt;2x ULN) after stopping TDF at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>assessed at delivery</time_frame>
    <description>Delivery &lt;37 weeks gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Adverse Birth Outcomes</measure>
    <time_frame>during pregnancy or up to 28 days after delivery</time_frame>
    <description>PTD, SAB, IUFD, neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident HIV infection during pregnancy</measure>
    <time_frame>at delivery</time_frame>
    <description>Maternal HIV infection with seroconversion to positive test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in Prenatal Care</measure>
    <time_frame>assessed at time of delivery</time_frame>
    <description>at least 4 ANC visits after 28 weeks GA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>Pregnant Women - Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be randomized to early initiation (enrollment at 14-28 weeks pregnant) vs standard initiation (at 28 weeks pregnant) of tenofovir disoproxil fumarate (TDF) 300 mg daily oral medication until delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newborn Infants - Lamivudine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants exposed to HBV at birth will be randomized to receive oral lamivudine post-exposure prophylaxis or matching placebo. Medication will be administered twice daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>oral TDF medication 300 mg daily</description>
    <arm_group_label>Pregnant Women - Tenofovir</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine Oral Solution</intervention_name>
    <description>Oral lamivudine with weight-based dosing BID from birth until 6 months of age</description>
    <arm_group_label>Newborn Infants - Lamivudine</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  prenatal clinic patient,&#xD;
&#xD;
          -  age â‰¥16 years,&#xD;
&#xD;
          -  14-27 weeks gestational age according to clinic dating based on LMP or ultrasound,&#xD;
&#xD;
          -  active hepatitis B with high risk of vertical transmission (HBsAg+, HBeAg+),&#xD;
&#xD;
          -  plan to receive follow up care and deliver at study facility,&#xD;
&#xD;
          -  capable of providing informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive (according to HIV antibody testing performed at the initial prenatal&#xD;
             visit)&#xD;
&#xD;
          -  known liver cirrhosis or end-stage liver disease,&#xD;
&#xD;
          -  elevated liver enzymes (ALT &gt;3x upper limit of normal),&#xD;
&#xD;
          -  elevated serum creatinine (&gt;1.4 mg/dl)&#xD;
&#xD;
          -  currently taking tenofovir medication&#xD;
&#xD;
          -  allergy or intolerance to tenofovir study medication,&#xD;
&#xD;
          -  known fetal anomaly in the current pregnancy,&#xD;
&#xD;
          -  clinical illness requiring hospitalization at the time of enrollment&#xD;
&#xD;
          -  evidence of early labor at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>eligible if pregnant</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jodie Dionne, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jodie Dionne, MD, MSPH</last_name>
    <phone>2059756530</phone>
    <email>jdionne@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie White</last_name>
    <phone>2059348145</phone>
    <email>jcarleen@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodie Dionne-Odom</last_name>
      <phone>205-975-6530</phone>
      <email>jdionne@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jodie A Dionne-Odom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jodie Dionne-Odom</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>perinatal infection, hepatitis B in pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

